Silexion Therapeutics Showcases Innovative Investments in Oncology

Author: Henry Turner Updated: 09-02-2025 08:58 AM

Silexion Therapeutics Announces Upcoming Presentation

In an exciting development for investors and healthcare professionals alike, Silexion Therapeutics Corp. (NASDAQ: SLXN), a pioneering biotechnology company focused on RNA interference (RNAi) therapies, is gearing up to present at a prominent investment conference. Scheduled to take place from September 8 to September 10, 2025, at a luxurious venue, this annual gathering will provide an excellent platform to showcase Silexion's innovative approach to tackling KRAS-driven cancers.

Significant Presentation Details

The anticipated presentation by Silexion’s senior management will occur on September 10, 2025, at 2:00 PM ET. A detailed slide deck has been made available on their official website, providing potential investors and interested parties with insights into the company’s vision and ongoing projects.

One-on-One Investor Meetings

Moreover, Silexion's management team is open to engaging with investors through one-on-one meetings during the conference. Investors seeking to connect personally can arrange such discussions through their H.C. Wainwright representatives or by contacting Silexion directly via email.

About Silexion Therapeutics

Silexion Therapeutics is at the forefront of cancer research, particularly in developing therapies aimed at treating cancers characterized by the mutated KRAS oncogene. This oncogene is recognized as one of the most common drivers of oncogenesis in humans, making Silexion's mission vital.

Recent Developments in Oncology Research

The company has made significant strides with its lead product candidate, which is currently undergoing clinical trials for locally advanced pancreatic cancer. Encouraging results from a previous Phase 2a trial demonstrated a promising efficacy profile compared to chemotherapy alone, sparking hope for better treatment options for patients battling this aggressive form of cancer.

Company Contacts

For any inquiries, please reach out to:
Silexion Therapeutics Corp.
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

For Capital Markets & Investor Relations:
Arx Capital Markets
North American Equities Desk
silexion@arxadvisory.com

Frequently Asked Questions

What is Silexion Therapeutics known for?

Silexion Therapeutics focuses on developing RNA interference therapies specifically targeting cancers associated with the KRAS oncogene.

When will Silexion present at the investment conference?

The presentation is scheduled for September 10, 2025, at 2:00 PM ET during the H.C. Wainwright Global Investment Conference.

How can investors meet with Silexion management?

Investors can arrange one-on-one meetings through their H.C. Wainwright representatives or by emailing Silexion directly.

What clinical trials is Silexion currently conducting?

Silexion is conducting trials for its lead product candidate aimed at locally advanced pancreatic cancer, with promising results indicated from previous studies.

Who should I contact for more information on Silexion?

For further inquiries, you can reach Ms. Mirit Horenshtein Hadar, CFO at Silexion Therapeutics, via email at mirit@silexion.com.

About The Author

Hi there, As a writer and financial specialist, Henry Turner is passionate about guiding people through the complex world of finance. Having worked in finance for many years, I am an expert at simplifying difficult financial ideas into understandable, useful insights for my blog and articles. My goal is to arm you with the confidence and information you need to make wise financial choices.

Writing for a number of financial blogs has allowed me to interact with readers from novice investors looking for fresh ideas to seasoned investors starting their financial journeys. My mission is to enable everyone to understand and access finance, so enabling you to confidently and clearly reach your financial goals. I appreciate you traveling with me toward success and financial literacy.

Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.